https://www.selleckchem.com/Androgen-Receptor.html Second, the boom in developing target therapies and checkpoint-blockade immunotherapy prolongs overall survival in HCC patients, re-emphasizing the importance of local tumor control. Remarkably, RT combines with systemic therapies to generate the systemic therapy augmented by radiotherapy effect, a benefit now being actively investigated. The evidence suggests that most vulnerable subjects to COVID-19 infection suffer from patients with comorbidities or immunosuppression, including liver transplant recipients. Liver graft dysfunction may be a rare complication. Some patients complain about the post-COVID-19 syndrome. The aim of this study was to assess medium and short-term outcomes in liver transplant patients. A retrospective case series was performed at a tertiary referral center. We screened 845 patients who had liver transplant (LT) in our center. All consecutive LT patients with COVID-19 during the Spanish outbreak from March 2020 to April 2021, were included. Demographics, pre-existing comorbidities, clinical and radiological data of COVID-19 infection, complications and liver graft function were assessed at diagnosis and 3-month follow-up. Overall, 20 LT patients were diagnosed with confirmed COVID-19. We included 16 patients that met the inclusion criteria, 8 nonhospitalised (50%) and 8 (50%) hospitalised patients were analyzed. The median follow-up was 5.33 months (IQR 3.06-8.26). One patient died during the follow-up. All patients presented some grade of respiratory or functional symptoms. Dyspnoea and fatigue were the most prevalent symptoms during the 3-months follow-up. No Liver graft dysfunction were reported despite of partial immunosuppression withdrawal in 4 patients (25%). One patient had cardiovascular complications. Our results suggest the presence of post-COVID-19 syndrome with mild residual physical and psychological dysfunction in this subgroup of patients at 3-month after COVID-19. However,